ACC 2025 29 - 31 March 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Authors : Darren K. McGuire¹; Neil R. Poulter²; Rodica Pop-Busui³; Sharon L. Mulvagh⁴; Nikolaus Marx⁵; Johannes Mann^6,7; Silvio E. Inzucchi⁸; Scott Emerson⁹; John E. Deanfield¹⁰; Matthew A Cavender¹¹; Stephen C. Bain¹²; Maria Sejersten Ripa¹³; G. Kees Hovingh¹³; Mette Gislum¹³; Kirstine Brown-Frandsen¹³; Mads Engelmann¹³; Jens-Peter David¹³; John B. Buse¹¹

Affiliations

View Details Hide Details

Keywords

Diabetes

Congress oral presentation

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)

Are you a healthcare professional?

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial